UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

Molecular therapy, 2010-02, Vol.18 (2), p.429-434

2010

Volltextzugriff (PDF)

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4721-4730

2006

Volltextzugriff (PDF)

Stathmin 1: a novel therapeutic target for anticancer activity

Expert review of anticancer therapy, 2008-09, Vol.8 (9), p.1461-1470

2008

Volltextzugriff (PDF)

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

Molecular therapy, 2012-03, Vol.20 (3), p.679

2012

Volltextzugriff (PDF)

Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver

Oncology, 2014-01, Vol.87 (1), p.21-29

2014

Volltextzugriff (PDF)

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-09, Vol.26 (27), p.4418-4425

2008

Volltextzugriff (PDF)

Systemic therapeutic gene delivery for cancer: crafting Paris' arrow

Current gene therapy, 2009-02, Vol.9 (1), p.45-60

2009

Volltextzugriff (PDF)

Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine

Clinical cancer research, 2011-01, Vol.17 (1), p.183-192

2011

Volltextzugriff (PDF)

Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex

Human gene therapy, 2011-11, Vol.22 (11), p.1331-1341

2011

Volltextzugriff (PDF)

Emergency use regulatory approval process for experimental gene-based therapy

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5488-5489

2008

Volltextzugriff (PDF)

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein

DNA and cell biology, 2011-09, Vol.30 (9), p.715-726

2011

Volltextzugriff (PDF)

Prolonged Production of NADPH Oxidase-Corrected Granulocytes after Gene Therapy of Chronic Granulomatous Disease

Proceedings of the National Academy of Sciences - PNAS, 1997-10, Vol.94 (22), p.12133-12138

1997

Volltextzugriff (PDF)

Compassionate approval process for experimental gene-based products

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1899-1900

2008

Volltextzugriff (PDF)

Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy

The journal of gene medicine, 2010-05, Vol.12 (5), p.403-412

2010

Volltextzugriff (PDF)

Ewing's Sarcoma : Development of RNA Interference-Based Therapy for Advanced Disease

ISRN oncology, 2012, Vol.2012 (2012), p.1-13

2012

Volltextzugriff (PDF)

560. GNE Gene Replacement in Hereditary Inclusion Body Myopathy

Molecular therapy, 2006-05, Vol.13 (S1), p.S215-S216

2006

Volltextzugriff (PDF)

Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver

Oncology, 2014, Vol.87 (1), p.21-29

2014

Volltextzugriff (PDF)

Hereditary Inclusion Body Myopathy (HIBM2)

Gene regulation and systems biology, 2009-01, Vol.3, p.181-190

2009

Volltextzugriff (PDF)

Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2)

Gene regulation and systems biology, 2008-06, Vol.2, p.243-252

2008

Volltextzugriff (PDF)

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

Molecular therapy, 2012-03, Vol.20 (3), p.679-686

2012

Volltextzugriff (PDF)

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)

Gene regulation and systems biology, 2008-06, Vol.2008 (2), p.GRSB.S728

2008

Volltextzugriff (PDF)

Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2

Gene regulation and systems biology, 2009-05, Vol.3, p.89-101

2009

Volltextzugriff (PDF)

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer : A phase II trial

Cancer research (Chicago, Ill.), 2000-11, Vol.60 (22), p.6359-6366

2000

Volltextzugriff (PDF)

Hereditary Inclusion Body Myopathy (HIBM2)

Gene Regulation and Systems Biology, 2009-01, Vol.2009 (3), p.GRSB.S2594

2009

Volltextzugriff (PDF)

Long Term Follow Up: Phase I Trial of “bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell” Immunotherapy (FANG™) in Advanced Cancer

Journal of vaccines & vaccination, 2013-12, Vol.4 (8)

Jacklyn Nemunaitis, Minal Barve

2013

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Englisch
(50)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(25)
Humans
(19)
Female
(14)
Adult
(11)
Male
(11)
Oncology
(10)
Aged
(9)
Gene Therapy
(9)
Genetics & Heredity
(9)
Middle Aged
(9)
Biological And Medical Sciences
(8)
Animals
(7)
Clinical Trials
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Medical Sciences
(5)
Medicine, Research & Experimental
(5)
Mutation
(5)
Neoplasms - Therapy
(5)
Research & Experimental Medicine
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

Stathmin 1: a novel therapeutic target for anticancer activity

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

Systemic therapeutic gene delivery for cancer: crafting Paris' arrow

Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine

Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex

Emergency use regulatory approval process for experimental gene-based therapy

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein

Prolonged Production of NADPH Oxidase-Corrected Granulocytes after Gene Therapy of Chronic Granulomatous Disease

Compassionate approval process for experimental gene-based products

Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy

Ewing's Sarcoma : Development of RNA Interference-Based Therapy for Advanced Disease

560. GNE Gene Replacement in Hereditary Inclusion Body Myopathy

Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver

Hereditary Inclusion Body Myopathy (HIBM2)

Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2)

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)

Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer : A phase II trial

Hereditary Inclusion Body Myopathy (HIBM2)

Long Term Follow Up: Phase I Trial of “bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell” Immunotherapy (FANG™) in Advanced Cancer

Suchergebnisse filtern